1 month
+8.4%
price return
Year to date
+11.9%
price return
Recent earnings
4/4
quarters beat
Big funds
8
hold this stock
News tone
Bullish
50 articles, 7 days
Analysts
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsWhat it reported, what was expected, and what comes next.
Reported Aug 4, 2026
Earnings per share
$0.68 expected
Revenue
$14.39B expected
GAAP EPS was -$0.04 and adjusted EPS was $0.77. The adjusted figure is comparable to consensus.
FY2026 guidance
$60.50B to $62.50B
No comparable estimate
Next report
EPS expected
$0.59 to $0.94
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
From the release
The three statements, quarter by quarter.
Sep 2025 to Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| RevenueTotal revenue | $16.65B | $17.56B | $14.45B | $15.03B |
| Cost of what it soldCost of revenue | $4.17B | $5.27B | $4.73B | $4.09B |
| Gross profit | $12.48B | $12.29B | $9.72B | $10.94B |
| What it spent | ||||
| Research and development | $3.94B | $3.42B | $2.63B | $2.81B |
| Sales and adminSelling, general and administrative | $3.19B | $4.08B | $2.96B | $3.41B |
| Other operating costsOperating costs not itemised in the filing's summary | $1.81B | $1.10B | $100.0M | — |
| Total operating expenses | $8.93B | $8.60B | $5.69B | $6.24B |
| What was left | ||||
| Operating profitOperating income | $3.55B | $3.69B | $4.03B | $4.71B |
| Interest on debtInterest expense | $652.0M | $711.0M | $668.0M | $667.0M |
| Profit before tax | $3.33B | -$1.64B | $3.17B | -$653.0M |
| TaxIncome tax expense | -$216.0M | -$2.0M | $461.0M | -$407.0M |
| Net profitNet income | $3.54B | -$1.65B | $2.69B | -$246.0M |
| EBITDAEarnings before interest, tax, depreciation, amortisation | $5.65B | $756.0M | $5.02B | $1.20B |
Business quality, value, and expectations at a glance.
Fundamentals
Reasonably priced and running thin margins.
Valuation
Quality
Growth
Filed positions and reported activity tied to this stock.
8 funds hold a position and insiders have been net selling.
Real smart money
Insiders
Politicians
Trend, range, and the price levels that matter.
Technicals
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
$26.7920D support
20D resistance
Returns
Price vs moving averages
Volume pace
Recent coverage and its overall tone.
News
Coverage is bullish
20 bullish · 29 neutral · 1 bearish
Tone of tracked coverage
Becton, Dickinson and Company (BDX) Stock forecasts
Leans bullishAug 11BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating
Leans bullishAug 11Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?
Leans bullishAug 11With Bank of America at Record Highs, Wall Street Is Bullish but Retail Is Wary
Leans bullishAug 11Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?
Leans bullishAug 11KMG Fiduciary Partners LLC Acquires 39,875 Shares of Pfizer Inc. $PFE
NeutralAug 11Keurig Dr Pepper Inc. (KDP) Stock Forecasts
NeutralAug 11Hawaiian Electric Industries, I (HE) Stock forecasts
NeutralAug 11$15K
sold
AlphaYou